🇺🇸 CYBIN INC.HELP

Company Update Form 6-K 16-11-2026 07:00:11 EST

Subject: 6-K — Foreign issuer report

Overview: Helus Pharma reported positive Phase 3 APPROACH study results for HLP003 as an adjunctive treatment for major depressive disorder, showing significant MADRS score improvements.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest